struvite and Chronic-Disease

Encrusted cystitis is a very rare chronic inflammatory disease of the bladder characterized by precipitation and incrustation of phosphate and ammonium-magnesium salts on the vescical mucosa, caused by urinary infection due to urolithic microorganisms. Corynebacterium urealyticum or Corynebacterium group D2, a multiple antibiotic-resistant urea-splitting bacterium, is the most frequently incriminated aetiology. We report a case of a 57-year-old man affected by systemic erythematosus lupus with a long history of dysuria and suprapubic pain who underwent percutaneous nephrostomy drainage with urethral stenting for lupoid obstructive uropathy. Before the diagnosis of encrusted cystitis by Corynebacterium urealyticum was established, the patient underwent five cystoscopies to remove the plaques and multiple unsuccessful antibiotic treatment courses. Eventually the infection was definitively cured after a two-week course with intramuscular teicoplanin.

Topics: Anti-Bacterial Agents; Apatites; Bacterial Proteins; Chemical Precipitation; Chronic Disease; Combined Modality Therapy; Corynebacterium; Corynebacterium Infections; Crystallization; Cystitis; Drug Resistance, Multiple, Bacterial; Humans; Hydronephrosis; Immunocompromised Host; Lupus Erythematosus, Systemic; Magnesium Compounds; Male; Nephrostomy, Percutaneous; Phosphates; Pyelitis; Remission Induction; Stents; Struvite; Teicoplanin; Urease

In a prospective, double-blind, placebo-controlled study, the efficacy and safety of acetohydroxamic acid (AHA) in preventing urinary calculogenesis was evaluated in 94 patients with chronic urinary infection. Stone growth occurred in 17% of the AHA group and in 46% of the placebo group (p less than 0.005). Completely reversible side effects consisting predominantly of psychoneurologic and musculo-integumentary symptoms were more prevalent in the AHA group (p less than 0.01). Side effects which were judged 'intolerable' were experienced by 10 (22.2%) of patients in the AHA group and 2 (4.1%) in the placebo group. It is concluded that AHA treatment is effective, relatively safe, and clinically useful in preventing infection-induced urinary calculogenesis.

Topics: Adult; Aged; Bacteriuria; Chronic Disease; Double-Blind Method; Female; Humans; Hydroxamic Acids; Magnesium; Magnesium Compounds; Male; Middle Aged; Palliative Care; Phosphates; Placebos; Prospective Studies; Struvite; Urinary Calculi

Topics: Chronic Disease; Humans; Kidney Calculi; Magnesium Compounds; Male; Middle Aged; Phosphates; Proteus Infections; Struvite; Urinary Tract Infections

Urine alkalinization favours the formation of calcium phosphate (CaP) and struvite stones. In this retrospective study we analyze the effect of chronic urinary acidification on phosphatic stone recurrence. Twenty-four patients with CaP-struvite recurrent stones and persistently high urinary pH were divided in two groups: group A, 11 patients who failed to lower the urinary pH below 5.5 during a standard acid load test: group B, 13 patients with preserved acidification power. Ammonium sulfate 2-3 g/day was given for 4.7 and 6.5 years to groups A and B, respectively. A persistent reduction in urinary pH, relative saturation for CaP and stone formation rate was observed in both groups. The treatment did not cause systemic acidosis as long as renal function remained normal. Urinary daily excretion of Ca and P as well as their renal tubular handling did not change with time. Results suggest acidifying agents might be useful in preventing recurrence of CaP-struvite stones even in the presence of a mild acidification defect and encourage undertaking properly controlled prospective trials.

Topics: Adult; Ammonium Sulfate; Calcium Phosphates; Chronic Disease; Drug Evaluation; Female; Humans; Hydrogen-Ion Concentration; Kidney Calculi; Magnesium; Magnesium Compounds; Male; Middle Aged; Phosphates; Recurrence; Retrospective Studies; Struvite; Time Factors

We have investigated and treated 176 patients who were suffering from renal calculi. The stones contained calcium in 87% of patients, predominantly urate in 11%, and rarely contained magnesium ammonium phosphate or cystine. Of the patients with calcium stones, hypercalciuria was present in 75% and was identified in 57% by the measurement of the 24-hour urinary calcium excretion, and in a further 18% by a standardization calcium "fast-and-load" test. Nine patients were found to have primary hyperparathyroidism and were treated surgically. A further 21% were suspected to have normocalcaemic hyperparathyroidism, and metabolic studies are being developed to clarify this. The treatment of hypercalciuria included a low-calcium diet, and various combinations of a thiazide diuretic, phosphate supplements and sodium cellulose phosphate. Hypercalciuria was controlled in all compliant patients, and only two developed further stones. Hyperuricosuria was rarely the sole metabolic abnormality in patients with calcium stones, though this might reflect the referral pattern of the Unit. Uric acid stones were frequently, but not invariably, associated with hyperuricosuria and acid urine, and even large uric acid calculi dissolved with a combined therapy of high fluid intake, allopurinol and an alkalinizing agent. Surgical treatment was rarely required in these patients. A stone in the renal pelvis of one patient was removed percutaneously and did not require ultrasonic fragmentation. Modern methods of investigation and treatment have greatly improved the outlook for patients with recurrent renal calculi.

Topics: Calcium; Chronic Disease; Combined Modality Therapy; Female; Humans; Hyperparathyroidism; Kidney Calculi; Magnesium; Magnesium Compounds; Male; Middle Aged; Phosphates; Recurrence; Struvite; Uric Acid